Hero Image

Pulmonary Arterial Hypertension: Signs & Treatment

Pulmonary Arterial Hypertension (PAH) is a serious, progressive condition that raises blood pressure in the arteries of your lungs.

Catching the signs early—and acting on them—can slow progression, improve quality of life, and, in some cases, open the door to treatments that meaningfully reverse the disease’s trajectory.

Early signs and symptoms of PAH

PAH often starts subtly. People commonly notice shortness of breath during routine activities (walking uphill, carrying groceries), unusual fatigue, a racing heartbeat, lightheadedness, or chest pressure. These symptoms can be mistaken for anxiety, low fitness, or asthma, which is why PAH is often diagnosed late. The NHLBI and the Pulmonary Hypertension Association both emphasize that persistent, progressive breathlessness deserves evaluation.

Clues it’s more than deconditioning include symptoms that steadily worsen, longer recovery time after exertion, swelling in the ankles or belly, bluish lips, or near-fainting on exertion. Keep a simple activity and symptom diary—note distance you can comfortably walk, stairs climbed, and any dizziness or chest discomfort—to share with your clinician.

Seek testing if symptoms persist beyond 6–8 weeks, escalate quickly, or appear alongside risk factors (connective tissue disease, congenital heart disease, HIV, portal hypertension, prior methamphetamine or anorexigen exposure, or a family history of PAH). An early evaluation can start with a primary care clinician and often leads to referral to a pulmonary hypertension center.

  • Breathlessness on exertion (early), at rest (later)
  • Fatigue and reduced exercise capacity
  • Chest pain or pressure, palpitations
  • Lightheadedness or fainting with activity
  • Leg/ankle swelling or abdominal bloating
  • Cold hands/feet, bluish lips or fingers

What causes PAH and who’s at risk?

PAH (Group 1 pulmonary hypertension) can be idiopathic, hereditary (often related to BMPR2 variants), or associated with conditions such as systemic sclerosis and other connective tissue diseases, congenital heart shunts, HIV, portal hypertension, and certain drugs/toxins. Females are affected more often than males. Importantly, other forms of pulmonary hypertension (due to left heart disease, chronic lung disease, or chronic blood clots) can mimic PAH—sorting this out matters because treatments differ.

If you have a known risk condition (for example, scleroderma), talk with your specialist about screening; periodic echocardiography and blood biomarkers can catch changes earlier in high-risk groups.

How PAH is diagnosed (and why speed matters)

A targeted workup rules out common lookalikes and confirms PAH. Typical steps include an echocardiogram, ECG, blood tests (e.g., BNP/NT-proBNP), pulmonary function testing, and a ventilation–perfusion (V/Q) scan to look for chronic blood clots. A V/Q scan is preferred over CT for screening chronic thromboembolic disease; learn more about the test here.

Definitive diagnosis requires a right heart catheterization, sometimes with vasoreactivity testing to see whether high-dose calcium channel blockers could help. Rapid referral to a specialized PH center is associated with better outcomes. Current recommendations are summarized in the peer-reviewed ESC/ERS Guidelines for pulmonary hypertension.

Can PAH be reversed?

There’s no universal “cure,” but PAH is increasingly treatable—and sometimes functionally reversible—especially when caught early. Many patients achieve low-risk status with modern combination therapy, meaning improved exercise capacity, normalized biomarkers, and better right-heart function.

True reversal depends on the cause: when severe PAH stems from certain congenital heart defects, timely surgical repair can normalize pressures. Chronic thromboembolic pulmonary hypertension (CTEPH), which can look like PAH, may be curable with surgery called pulmonary endarterectomy or with balloon pulmonary angioplasty when surgery isn’t feasible. For Group 1 PAH, long-term medical therapy, and in select cases lung or heart–lung transplantation, can dramatically improve survival and function.

Treatment options: from Adempas (riociguat) to combination therapy

PAH therapy targets three main pathways involved in blood vessel narrowing and remodeling: endothelin, nitric oxide, and prostacyclin. Your team will likely use risk-based, combination therapy tailored to your symptoms, right-heart function, and test results. The PHA treatment overview is a helpful primer.

Soluble guanylate cyclase (sGC) stimulator: Adempas (riociguat)

What it does: Riociguat enhances the nitric oxide pathway to relax pulmonary arteries and reduce pressure. It’s approved for PAH and for inoperable or persistent/recurrent CTEPH.

Considerations: It can improve exercise capacity and hemodynamics but may cause low blood pressure, headache, dizziness, and reflux. It has a boxed warning for embryo–fetal toxicity and requires strict pregnancy prevention and enrollment in a REMS program; it must not be combined with PDE5 inhibitors (e.g., sildenafil, tadalafil) or nitrates. See the FDA label for details: Adempas (riociguat).

Phosphodiesterase-5 (PDE5) inhibitors

Examples: Sildenafil (Revatio) and tadalafil (Adcirca) also augment the nitric oxide pathway and are widely used, often as part of initial dual therapy. Common side effects include headache, flushing, and nasal congestion; they should not be used with nitrates. Learn more about sildenafil and tadalafil.

Endothelin receptor antagonists (ERAs)

Examples: Ambrisentan, bosentan, and macitentan block endothelin, a potent vasoconstrictor. They improve symptoms and delay clinical worsening; macitentan and ambrisentan are commonly used in combination with PDE5 inhibitors. Side effects can include fluid retention and anemia; bosentan requires liver function monitoring. More on ambrisentan and macitentan.

Prostacyclin pathway therapies

Examples: Epoprostenol (IV), treprostinil (IV/subcutaneous/inhaled/oral), and iloprost (inhaled) are potent vasodilators and antiremodeling therapies for moderate-to-severe PAH. The oral IP receptor agonist selexipag (Uptravi) extends this pathway to pill form. These drugs are highly effective, particularly in advanced disease; continuous infusions can be life-saving but require catheter care and have side effects (headache, jaw pain, flushing). Read more on epoprostenol and selexipag.

Calcium channel blockers (for a small subset)

A minority of patients demonstrate acute vasoreactivity during catheterization and may benefit from high-dose amlodipine, diltiazem, or nifedipine. This approach is only for the vasoreactive subset and should not be started without proper testing and specialist supervision.

Supportive care and advanced options

  • Diuretics to control swelling; careful dosing avoids kidney strain.
  • Oxygen if oxygen levels drop with activity or sleep.
  • Anticoagulation for CTEPH or select PAH patients as advised by specialists.
  • Cardiopulmonary rehabilitation improves endurance and confidence; many PH centers offer programs.
  • Transplantation (lung or heart–lung) for refractory, advanced cases.
  • Clinical trials: consider enrollment to access cutting-edge therapies (ClinicalTrials.gov).

Why early recognition changes outcomes

Starting therapy when the right ventricle is still compensating leads to better long-term results, fewer hospitalizations, and a higher chance of achieving low-risk status. Modern strategies often begin with dual oral therapy (ERA + PDE5 inhibitor) and escalate quickly to include riociguat or prostacyclin agents if targets aren’t met, following guideline-based risk assessment.

Track your progress with measurable goals: walking distance (e.g., six-minute walk), symptom class, NT-proBNP levels, and echocardiographic/right-heart catheter metrics. If goals aren’t met within a few months, ask your team about intensification or referral to a PH center with expertise in advanced therapies.

Living well with PAH: practical steps

  • Move safely: Light-to-moderate, supervised exercise is beneficial; avoid heavy lifting or breath-holding maneuvers.
  • Limit salt and monitor weight: Sudden gains may signal fluid retention—call your team.
  • Vaccinate: Stay current on influenza and pneumococcal vaccines to prevent lung infections.
  • Avoid high altitude and stop smoking: Low oxygen and tobacco strain the pulmonary circulation.
  • Plan pregnancy carefully: PAH and pregnancy carry high risk; if pregnancy is possible, discuss reliable contraception and preconception counseling.
  • Know your meds: Carry a list of therapies; avoid drug interactions (nitrates with PDE5 inhibitors; PDE5 inhibitors with riociguat).
  • Build a team: Seek care at an experienced PH center and connect with reputable patient communities like the Pulmonary Hypertension Association.

When to seek urgent care

  • Chest pain, fainting, or severe breathlessness at rest
  • New confusion, blue lips, or coughing up blood
  • Rapid swelling, especially with decreased urine output

These symptoms can signal right-heart strain or decompensation and warrant immediate evaluation.

Key takeaways

  • Listen to early clues: progressive breathlessness, fatigue, and near-syncope are not “just being out of shape.”
  • Confirm the diagnosis quickly with echocardiography, a V/Q scan, and right heart catheterization.
  • PAH may not be curable, but early, aggressive, guideline-based treatment—including options like Adempas (riociguat)—can restore function and extend life.
  • Partner with a PH center, set measurable goals, and escalate therapy promptly if targets aren’t met.

If you’re experiencing persistent symptoms or have risk factors, schedule an appointment and bring a symptom diary. Early recognition is your greatest advantage.